Maternal and neonatal outcomes in a treated versus non- treated cohort of women with Gestational Diabetes Mellitus according to the HAPO 5 and 4 criteria
PDF
Cite
Share
Request
Original Papers
VOLUME: 9 ISSUE: 3
P: 133 - 140
September 2017

Maternal and neonatal outcomes in a treated versus non- treated cohort of women with Gestational Diabetes Mellitus according to the HAPO 5 and 4 criteria

Facts Views Vis ObGyn 2017;9(3):133-140
1. Department of Obstetrics and gynecology, University Hospital of Ghent, 9000 Ghent, Belgium
2. Department of Obstetrics and gynecology, Jan Yperman Hospital, 8900 Yper, Belgium
No information available.
No information available
PDF
Cite
Share
Request

Abstract

Background

Our aim was to evaluate the treatment effect of gestational diabetes mellitus (GDM) according to the Hyperglycemia and Adverse Pregnancy Outcome group (HAPO) screening.

Results

The prevalence of GDM, using HAPO 5 was 23.8%. Of these, 72.8% were treated. Comparison of outcomes between treated and untreated patients showed no differences. The prevalence of GDM according to HAPO 4 criteria was 16.9%. In the untreated group, there were more cases of (pre)eclampsia (P=0.038), more admissions to neonatal care department (P=0.036), pregnancy duration was shorter (P=0.05), and Apgar score at five minutes was significantly lower (P=0.019). The outcomes didn’t differ in the MAGG (midly aberrant glycemic group).

Conclusions

Using HAPO 5 criteria in population-based screening doubled the prevalence of GDM. There were no differences between untreated and treated HAPO 5 and MAGG patients, while in the HAPO 4 group there might be a trend of therapy effectiveness.

Keywords:
Gestational Diabetes Mellitus, screening, mildly glycemic aberrant pregnant women, HAPO 5 criteria, HAPO 4 criteria, IADPSG criteria